Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 83,934 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: therapy Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Squalamine for the Treatment in Proliferative Diabetic Retinopathy

NCT01769183
View directory record Official record
Conditions
Retinal Neovascularization
Interventions
Squalamine Lactate ophthalmic solution 0.2%
Drug
Lead sponsor
Elman Retina Group
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 10, 2015 · Synced Oct 31, 2026, 2:32 PM EDT
Active, not recruiting Phase 2 Interventional

Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism

NCT06531941
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
400 µg of MBX 2109 once-weekly by subcutaneous injection, 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection
Drug
Lead sponsor
MBX Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
17
States / cities
Miami, Florida • Macon, Georgia • Jackson, Mississippi + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 31, 2026, 2:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine Vepdegestrant

NCT06275841
View directory record Official record
Conditions
Healthy
Interventions
vepdegestrant, esomeprazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Oct 31, 2026, 2:32 PM EDT
Recruiting Phase 2 Interventional

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

NCT07323641
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Osimertinib, Survey Administration, Telisotuzumab Vedotin
Procedure · Drug · Other + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 31, 2026, 2:32 PM EDT
Not listed Phase 2 Interventional

A Phase II Study of AS1411 in Renal Cell Carcinoma

NCT00740441
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
AS1411
Drug
Lead sponsor
Antisoma Research
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Duarte, California • Sacramento, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2009 · Synced Oct 31, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Results available

Selonsertib in Adults With Pulmonary Arterial Hypertension

NCT02234141
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Placebo, Selonsertib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
24
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 31, 2026, 2:32 PM EDT
Terminated Phase 2 Interventional Results available

Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia

NCT03071276
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Selinexor, Fludarabine, Cytarabine, methotrexate/hydrocortisone/cytarabine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 24 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
7
States / cities
Phoenix, Arizona • Palo Alto, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 22, 2020 · Synced Oct 31, 2026, 2:32 PM EDT
Not yet recruiting Phase 1 Interventional

Study of Intramyocardial Injection of Ventrix Bio Extracellular Matrix (VentriGel) to Assess the Safety and Feasibility in Pediatric Patients with Hypoplastic Left Heart Syndrome (HLHS)

NCT06461676
View directory record Official record
Conditions
Hypoplastic Left Heart Syndrome
Interventions
Ventrix Bio Extracellular Matrix
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 1 Year
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 31, 2026, 2:32 PM EDT
Completed Not applicable Interventional

Microcurrent Treatment for Chronic Debilitating Pain

NCT04011176
View directory record Official record
Conditions
Pain, Opioid Use
Interventions
Standard treatment + placebo, Standard treatment + Microcurrent Therapy
Procedure
Lead sponsor
Paul Crawford
Federal
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Nellis Air Force Base, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 31, 2026, 2:32 PM EDT
Completed Not applicable Interventional Results available

Living in Full Even With Pain Study

NCT03916276
View directory record Official record
Conditions
Musculoskeletal Pain, Chronic Pain
Interventions
Cognitive Therapy (CT), Mindfulness Meditation (MM), Behavioral Activation (BA)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 31, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Results available

Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma

NCT01470417
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Chemotherapy, Chemotherapy + ChemoRadiotherapy
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 31, 2026, 2:32 PM EDT
Not listed Phase 2 Interventional

Use of Organic Germanium or Placebo for the Prevention of Radiation Induced Fatigue

NCT00651417
View directory record Official record
Conditions
Localized Breast Cancer, Localized Prostate Cancer, Patients Receiving External Beam Radiotherapy
Interventions
Organic Germanium, Placebo
Dietary Supplement
Lead sponsor
Arizona Oncology Services
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Oct 31, 2026, 2:32 PM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer

NCT01436968
View directory record Official record
Conditions
Prostate Cancer
Interventions
Aglatimagene besadenovec + valacyclovir, Placebo + valacyclovir
Biological
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2030
U.S. locations
72
States / cities
Gilbert, Arizona • Glendale, Arizona • Peoria, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 31, 2026, 2:32 PM EDT
Completed Not applicable Interventional

Reducing Residual Depressive Symptoms With Web-based Mindful Mood Balance

NCT02190968
View directory record Official record
Conditions
Major Depressive Disorder, Recurrent, in Remission, Depressive Symptoms
Interventions
Usual Depression Care, Mindful Mood Balance
Behavioral
Lead sponsor
University of Toronto
Other
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Oct 31, 2026, 2:32 PM EDT
Completed Phase 2 Interventional

A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma

NCT05156268
View directory record Official record
Conditions
Endometrial Carcinosarcoma
Interventions
Pembrolizumab, Olaparib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 31, 2026, 2:32 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A

NCT02137850
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A
Interventions
turoctocog alfa pegol
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
0 Years to 6 Years · Male only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
34
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 31, 2026, 2:32 PM EDT
Completed Phase 3 Interventional Results available

Dexmedetomidine as a Rapid Bolus in Children for Emergence Agitation

NCT01528891
View directory record Official record
Conditions
Tonsillectomy
Interventions
Dexmedetomidine, Placebo
Drug · Other
Lead sponsor
Peter Davis
Other
Eligibility
4 Years to 10 Years
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Oct 31, 2026, 2:32 PM EDT
Completed Phase 1 Interventional

IVIg to Treat BK Viremia in Kidney Transplant Recipients

NCT02659891
View directory record Official record
Conditions
Kidney Transplantation, BK Virus, Isoantibodies
Interventions
IVIg, Placebo
Biological · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 31, 2026, 2:32 PM EDT
Active, not recruiting No phase listed Observational

Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in Genitourinary Malignancies (CTC Immune Based Biomarkers)

NCT02978118
View directory record Official record
Conditions
Carcinoma, Renal Cell, Carcinoma, Urothelial
Interventions
Immune cell and CTC detection procedures
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 31, 2026, 2:32 PM EDT
Terminated Not applicable Interventional

A Feasibility Study on Ultrafiltration and Blood Volume Measurements

NCT04241718
View directory record Official record
Conditions
Acute Decompensated Heart Failure, Fluid Overload
Interventions
Aquadex FlexFlow System and BVA-100
Device
Lead sponsor
Nuwellis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Naperville, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 31, 2026, 2:32 PM EDT
Terminated Phase 2 Interventional Results available

Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy

NCT00490490
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Bexxar (tositumomab), External beam radiotherapy (XRT), Potassium Iodide (KI)
Drug · Procedure
Lead sponsor
Stanford University
Other
Eligibility
19 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 31, 2026, 2:32 PM EDT
Completed Not applicable Interventional

Supplemental Perioperative Oxygen to Reduce Surgical Site Infection After High Energy Fracture Surgery

NCT01798810
View directory record Official record
Conditions
Post Operative Surgical Site Infection
Interventions
Supplemental Perioperative Oxygen
Procedure
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 80 Years
Enrollment
1,171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
2
States / cities
Phoenix, Arizona • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 31, 2026, 2:32 PM EDT
Completed Early Phase 1 Interventional

Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery

NCT00601913
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
erlotinib hydrochloride, protein analysis, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, liquid chromatography, mass spectrometry, neoadjuvant therapy, therapeutic conventional surgery
Drug · Genetic · Other + 1 more
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 31, 2026, 2:32 PM EDT
Completed Early Phase 1 Interventional

Fecal Microbial Transplantation for C. Difficile and/or Ulcerative Colitis or Indeterminate Colitis

NCT03268213
View directory record Official record
Conditions
Clostridium Difficile Infection, Ulcerative Colitis, Indeterminate Colitis
Interventions
Fecal Microbial Transplantation
Biological
Lead sponsor
Stony Brook University
Other
Eligibility
7 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 31, 2026, 2:32 PM EDT